Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Oncology

• Publication date

  2006-08-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2005.05.1490PMID 16921047
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

  2007cited by this paper
• A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer

  2005cited by this paper
• Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG)

  2005cited by this paper
• Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

  2005cited by this paper
• Radiation therapy and tamoxifen: concurrent or sequential? That is the question.

  2005cited by this paper
• A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC).

  2004cited by this paper
• Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

  2004cited by this paper
• A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer.

  2004cited by this paper
• Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

  2004cited by this paper
• Chemotherapy for advanced pancreatic cancer.

  2003cited by this paper
• Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

  2003cited by this paper
• Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma

  2002cited by this paper
• Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

  2002cited by this paper
• Gemcitabine-based combination treatment of pancreatic cancer.

  2002cited by this paper
• Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage.

  2001cited by this paper
• Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma

  2001cited by this paper
• Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.

  2000cited by this paper
• Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer.

  2000cited by this paper
• An investigational new drug treatment program for patients with gemcitabine

  1999cited by this paper
• Combination chemotherapy studies with gemcitabine.

  1997cited by this paper
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997cited by this paper
• Pancreatic carcinoma.

  1997cited by this paper
• A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.

  1996cited by this paper
• Interaction between cisplatin and gemcitabine in vitro and in vivo.

  1995cited by this paper
• Schedule-dependent antitumor effect of gemcitabine in in vivo model system.

  1995cited by this paper
• Measuring the quality of life of cancer patients: a concise QL-index for use by physicians.

  1981cited by this paper
• [Cancer of the pancreas].

  1965cited by this paper

• Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)

  2025cites this paper
• Global Status of Research on Quality of Life in Pancreatic Cancer Patients: A Bibliometric and Network Analysis from 2005-2024.

  2025cites this paper
• Nanoparticle-induced toxicity in pancreatic cancer: Insights from machine learning models

  2025cites this paper
• Engineered a Gemcitabine Nano-Prodrug Targeting Desmoplastic Pancreatic Tumor with Dual Enhancement of Penetration Dynamics.

  2025cites this paper
• Recent Advances and Challenges in the Treatment of Advanced Pancreatic Cancer: An Update on Completed and Ongoing Clinical Trials

  2025influential citation
• Sustainable Healing: Natural Compounds Facilitating the Future Cancer Treatment

  2025cites this paper
• Indian Consensus Guidelines for the Management of Pancreatic Cancer

  2025cites this paper
• Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group

  2024cites this paper
• Modeling health outcomes associated with BRCA testing and treatment strategies for patients with metastatic pancreatic cancer.

  2024cites this paper
• Chemotherapy and radiotherapy for advanced pancreatic cancer.

  2024cites this paper
• Variability of quality-of-life measurements and reporting in randomised controlled trials of pancreatic cancer: a systematic review

  2024cites this paper
• S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1

  2024cites this paper
• The Reallife Comparison of FOLFIRINOX vs Gemcitabine Platinum Combination as a First-Line Treatment in Patients with Pancreatic Carcinoma

  2024cites this paper
• Platinum-based targeted chemotherapies and reversal of cisplatin resistance in non-small cell lung cancer (NSCLC).

  2024cites this paper
• Efficacy of Cisplatin-Containing Chemotherapy Regimens in Patients of Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis

  2024cites this paper
• Consensus, debate, and prospective on pancreatic cancer treatments

  2024cites this paper
• Systemic Therapy for Metastatic Pancreatic Cancer—Current Landscape and Future Directions

  2024cites this paper
• A rat-based preclinical platform facilitating transcatheter hepatic arterial infusion in immunodeficient rats with liver xenografts of patient-derived pancreatic ductal adenocarcinoma

  2024cites this paper
• A Phase II Trial of Flouro-Gem as a First Line Treatment of Metastatic Adenocarcinoma of the Pancreas (GEFLUPAN trial)

  2024influential citation
• Efficacy and safety of first-line chemotherapies for patients with advanced pancreatic ductal adenocarcinoma: A systematic review and network meta-analysis

  2024cites this paper
• Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?

  2023influential citation
• Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for Molecular Analyses and Chemosensitivity Testing

  2023cites this paper
• Advances in the management of pancreatic cancer

  2023cites this paper
• Gemcitabine effects on tumor microenvironment of pancreatic cancer: Special focus on resistance mechanisms and metronomic therapies.

  2023cites this paper
• A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)

  2023cites this paper
• Liposomal Nanostructures for Gemcitabine and Paclitaxel Delivery in Pancreatic Cancer.

  2023cites this paper
• Preoperative treatments in borderline resectable and locally advanced pancreatic cancer: current evidence and new perspectives.

  2023cites this paper
• Gemcitabine Inhibits the Progression of Pancreatic Cancer by Restraining the WTAP/MYC Chain in an m6A-Dependent Manner

  2023influential citation
• Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma

  2023cites this paper
• Can Platinum Plus Gemcitabine be an Alternative to Folfirinox?

  2023cites this paper
• Synergistic effects of resveratrol with gemcitabine in pancreatic cancer chemotherapy by inhibiting the c-Met/PARP1 axis

  2023cites this paper
• A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer

  2023cites this paper
• Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine

  2023cites this paper
• Evaluation of Systemic Treatments of Small Intestinal Adenocarcinomas

  2023cites this paper
• Therapie des metastasierten Pankreaskarzinoms

  2022cites this paper
• Pancreatic head vs pancreatic body/tail cancer: Are they different?

  2022cites this paper
• Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised clinical trial.

  2022cites this paper
• The efficacy and safety of gemcitabine-based combination therapy vs. gemcitabine alone for the treatment of advanced pancreatic cancer: a systematic review and meta-analysis

  2022cites this paper
• Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma

  2022cites this paper
• Amivantamab: A new hope in targeting non-small cell lung cancer.

  2022cites this paper
• Evofosfamide and Gemcitabine Act Synergistically in Pancreatic Cancer Xenografts by Dual Action on Tumor Vasculature and Inhibition of Homologous Recombination DNA Repair

  2022cites this paper
• Real‐world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first‐line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma

  2022cites this paper
• Development of doped ZnO-based biomimicking and tumor-targeted nanotheranostics to improve pancreatic cancer treatment

  2022cites this paper
• Platinum-Based Chemotherapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: Summary of Evidence and Application in Clinical Practice

  2022cites this paper
• Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview

  2022cites this paper
• Macrophage C/EBPδ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner

  2022cites this paper
• Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities

  2022cites this paper
• Estimation of the organ of origin of peri-ampullary malignancy by preoperative CT scan

  2022cites this paper
• Options in First Line Management of Metastatic Pancreatic Cancer and the Determinative Role of ECOG Performance Status

  2022influential citation
• Platinum-based chemotherapy via nanocarriers and co-delivery of multiple drugs.

  2021cites this paper
• Effective Oncoleaking Treatment of Pancreatic Cancer by Claudin-Targeted Suicide Gene Therapy with Clostridium perfringens Enterotoxin (CPE)

  2021cites this paper
• Performance status as prognostic factor in phase III trials of first‐line chemotherapy of unresectable or metastatic pancreatic cancer: A trial‐level meta‐analysis

  2021cites this paper
• Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma.

  2021cites this paper
• Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial

  2021cites this paper
• Identification of DNA methylation-driven genes and construction of a nomogram to predict overall survival in pancreatic cancer

  2021cites this paper
• Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

  2021cites this paper
• HIF-1-dependent heme synthesis promotes gemcitabine resistance in human non-small cell lung cancers via enhanced ABCB6 expression

  2021cites this paper
• Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report

  2021cites this paper
• A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer

  2021cites this paper
• Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain.

  2021cites this paper
• Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer

  2021cites this paper
• The Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients

  2021cites this paper
• Stress Granules in the Anti-Cancer Medications Mechanism of Action: A Systematic Scoping Review

  2021cites this paper
• Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer

  2021cites this paper
• High intensity focused ultrasound for pancreatic cancer

  2021cites this paper
• Возможности химиотерапии у больных местно-распространенным и метастатическим аденогенным раком поджелудочной железы

  2020cites this paper
• Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer

  2020cites this paper
• Tackling DNA damage repair mechanisms—a promising molecular informed therapeutic approach in pancreatic ductal adenocarcinoma

  2020cites this paper
• Intraperitoneal gemcitabine chemotherapy is safe for patients with resected pancreatic cancer: final clinical and pharmacologic data from a phase II protocol and recommended future directions.

  2020cites this paper
• Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients

  2020cites this paper
• Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study.

  2020cites this paper
• Tumor growth kinetics by CA 19-9 in patients with unresectable pancreatic cancer receiving chemotherapy: A retrospective analysis.

  2020cites this paper
• Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma

  2020cites this paper
• CMAR_A_211151 2731..2742

  2020cites this paper
• Autophagy-related microRNAs: Possible regulatory roles and therapeutic potential in and gastrointestinal cancers.

  2020cites this paper
• DBDx-based drug combinations show highly potent therapeutic efficacy against human pancreatic cancer xenografts in athymic mice

  2020cites this paper
• CT-guided 125I brachytherapy combined with chemotherapy for the treatment of unresectable or locally advanced pancreatic carcinoma.

  2020cites this paper
• Pancreatoduodenectomy With Arterial Resection for Locally Advanced Pancreatic Cancer of the Head

  2020cites this paper
• Cisplatin Plus Gemcitabine as Standard of Care for Germline BRCA/PALB2-Mutated Pancreatic Adenocarcinoma: Are We Moving Too Fast?

  2020cites this paper
• Association of Jagged1 expression with malignancy and prognosis in human pancreatic cancer

  2020cites this paper
• BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects

  2020cites this paper
• Carcinoma of the Pancreas

  2020cites this paper
• Duration of therapy for locally advanced pancreatic cancer: Does it matter?

  2020cites this paper
• Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)

  2020cites this paper
• Evaluating the Sensitivity of Sporadic Pancreatic Cancer to poly(ADP-ribose) polymerase (PARP) Inhibition (Velaparib, Olaparib, AG14361) as Single Agents and as Chemo-sensitizers

  2020cites this paper
• Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).

  2020cites this paper
• Title: Evaluating the Sensitivity of Sporadic Pancreatic Cancer to poly(ADP-ribose) polymerase (PARP) Inhibition (Velaparib, Olaparib, AG14361) as Single Agents and as Chemo-sensitizers Running Title: The Sensitivity of Pancreatic Cancer to PARP Inhibition

  2020cites this paper
• COMPARISON OF THREE FIRST-LINE TREATMENTS IN ADVANCED PANCREATIC CANCER PATIENTS OLDER THAN 65 YEARS OF AGE: SINGLE-CENTRE EXPERIENCE

  2020influential citation
• Aortoesophageal fistula involving the central aortic arch salvaged with emergent percutaneous TEVAR, great vessel coverage and in vivo graft fenestration.

  2020cites this paper
• FOLFIRINOX in pancreatic cancer: from state of the art treatments to promising translational studies for personalized therapy

  2020cites this paper
• Complete Response of Metastatic Pancreatic Cancer In A CHEK2 Mutation Carrier Treated With Platinum-Based Therapy- A Case Report And Literature Review

  2020cites this paper
• Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression?

  2020cites this paper
• Medikamentöse Therapie des Pankreaskarzinoms: Was gibt es Neues?

  2020cites this paper
• Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice

  2020cites this paper
• New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism

  2019cites this paper
• Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND).

  2019cites this paper
• Special Section on Drug Delivery Technologies — Minireview Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer

  2019cites this paper
• Medikamentöse Therapie des Pankreaskarzinoms: Was gibt es Neues?

  2019cites this paper
• Gemcitabine Combination Nano Therapies for Pancreatic Cancer

  2019cites this paper
• Development of microRNA-based therapy for pancreatic cancer

  2019cites this paper